Neddylation and anti-tumor immunity

Xiaoguang Wang; Scott Best; Alexey V. Danilov

doi:10.18632/oncotarget.28019

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Neddylation and anti-tumor immunity

Xiaoguang Wang, Scott Best and Alexey V. Danilov _

PDF | Full Text | How to cite

Oncotarget. 2021; 12:2227-2230. https://doi.org/10.18632/oncotarget.28019

Metrics: PDF 894 views | Full Text 2639 views | ?

Abstract

Xiaoguang Wang1, Scott Best2 and Alexey V. Danilov1

1 Department of Hematology and Hematopoietic Stem Cell Transplant, City of Hope National Medical Center, Duarte, CA, USA

2 Molecular and Cellular Biology, University of Washington, Seattle, WA, USA

Correspondence to:

Alexey V. Danilov,

email:

[email protected]

Keywords: neddylation; T cell; pevonedistat

Received: June 10, 2021 Accepted: June 21, 2021 Published: October 12, 2021

Copyright: © 2021 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Contrary to chemotherapy, novel targeted therapies are associated with diverse immunomodulatory effects. Nedd8 is a small ubiquitin-like modifier that is involved in regulation of protein degradation. Neddylation is a promising target in cancer. Pevonedistat, a small molecule inhibitor of the Nedd8-activating enzyme, demonstrates pre-clinical activity in multiple tumor types. Recent studies have revealed that neddylation is important in immunity. We and others have shown that interfering with neddylation causes downstream immunomodulatory effects potentially leading to enhanced anti-tumor immunity. Thus, Nedd8 is a promising target in immuno-oncology.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28019

Publication Alerts

Research Perspectives:

Neddylation and anti-tumor immunity

Abstract